“Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.”
BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D., Ph.D. , from Roswell Park Comprehensive Cancer Center in Oncotarget's Volume 15 on March 15, 2024, entitled, “ From osimertinib to preemptive combinations .”
“Here, I suggest that while first-line osimertinib extends median progression-free survival (PFS) in EGFR-mutant lung cancer compared to first-generation TKIs, it reduces individual PFS in 15–20% of patients compared to first-generation TKIs. Since detecting a single resistant cell before treatment is usually impossible, osimertinib must be used in all patients as a first-line treatment, raising median PFS overall but harming some.
The simplest remedy is a preemptive combination (PC) of osimertinib and gefitinib. A comprehensive PC (osimertinib, afatinib/gefitinib, and capmatinib) could dramatically increase PFS for 80% of patients compared to osimertinib alone, without harming anyone. This article also explores PCs for MET-driven lung cancer.”
Continue reading: DOI: https://doi.org/10.18632/oncotarget.28569
Correspondence to: Mikhail V. Blagosklonny
Emails: Blagosklonny@oncotarget.com , Blagosklonny@rapalogs.com
Keywords: lung cancer NSCLC, EGFR, resistance, afatinib, gefitinib, capmatinib
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget : Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline , PubMed Central , Scopus , EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget , visit Oncotarget.com and connect with us on social media:
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com .
Oncotarget Journal Office
6666 East Quaker Street., Suite 1A
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
###
Oncotarget
Commentary/editorial
People
From osimertinib to preemptive combinations
15-Mar-2024